Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

Bernard, Gordon R., Ely, E. Wesley, Wright, Theressa J., Fraiz, Joseph, Stasek, Jerome E., Russell, James A., Mayers, Irvin, Rosenfeld, Brian A., Morris, Peter E., Yan, S. Betty, Helterbrand, Jeffery D.·2001·Critical Care Medicine

Abstract

OBJECTIVES: To assess the safety and effect on coagulopathy of a range of doses of recombinant human activated protein C (rhAPC). To determine an effective dose and duration of rhAPC for use in future clinical trials. DESIGN: Double-blind, randomized, placebo-controlled, multicenter, dose-ranging (sequential), phase II clinical trial. SETTING: Forty community or academic medical institutions in United States and Canada. PATIENTS: One hundred thirty-one adult patients with severe sepsis. INTERVENTIONS: Intravenous infusion of rhAPC (12, 18, 24, or 30 microg/kg/hr) or placebo for 48 or 96 hrs. MEASUREMENTS AND MAIN RESULTS: No significant differences in incidence of serious bleeding events (4% rhAPC, 5% placebo, p >.999) or incidence of serious adverse events (39% rhAPC, 46% placebo, p = 0.422) between rhAPC- and placebo-treated patients were observed. One of 53 rhAPC-treated patients with suitable immunogenicity samples had a low level, transient, non-neutralizing anti-APC antibody response not associated with any clinical adverse event. Significant dose-dependent decreases in both D-dimer (p <0.001) and end of infusion interleukin 6 levels (p =.021) were demonstrated. No statistically significant effects on fibrinogen or platelet counts were observed. A nonstatistically significant 15% relative risk reduction in 28-day all-cause mortality was observed between rhAPC- and placebo-treated patients. CONCLUSIONS: rhAPC was safe and well-tolerated and demonstrated a dose-dependent reduction in D-dimer and interleukin 6 levels relative to placebo. The dose of 24 microg/kg/hr for 96 hrs was selected for use in future clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00003246-200111000-00003

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 48 references

Cited by

See all 271

Metadata

Authors
Bernard, G. R., Ely, E. W., Wright, T. J., Fraiz, J., Stasek, J. E., Russell, J. A., Mayers, I., Rosenfeld, B. A., Morris, P. E., Yan, S. B., & Helterbrand, J. D.
Venue
Critical Care Medicine
Published
2001-11
Volume
29
Issue
11
Pages
2051-2059
ISSN
0090-3493 (ISSN-L)
OpenAlex
W1980233581
Cited by
271
References
48
FWCI
19.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. https://app.cochat.ai/papers/10.1097/00003246-200111000-00003
The paper
Bernard, G. R., Ely, E. W., Wright, T. J., Fraiz, J., Stasek, J. E., Russell, J. A., Mayers, I., Rosenfeld, B. A., Morris, P. E., Yan, S. B., & Helterbrand, J. D. (2001). Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Critical Care Medicine. https://doi.org/10.1097/00003246-200111000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.